Navigation Links
ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:10/30/2008

isks related to ISTA's ability to properly manage its growth; uncertainties and risks regarding the continued timely performance by ISTA's strategic partners of their respective obligations under existing collaborations and licensing arrangements; uncertainties and risks related to the continued availability of third party sourced products and raw materials on commercially reasonable terms, or at all; uncertainties and risks related to successful compliance with FDA and/or other governmental regulations applicable to ISTA's facilities, products and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property rights held by third parties; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2007, and its Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2008.

ISTA Pharmaceuticals, Inc.

Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenue

Product sales, net $21,604 $15,796 $54,749 $39,497

License revenue 69 69 208 208

Total revenue 21,673 15,865 54,957 39,705

Cost of products sold 5,806 4,197 14,761 10,417

Gross profit margin 15,867 11,668
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results
2. Onyx Pharmaceuticals Announces Third Quarter 2008 Financial Results Teleconference and Webcast
3. PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers*
4. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
5. Watson Pharmaceuticals Reports Third Quarter 2008 Results
6. Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences
7. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
10. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
11. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 23, 2015 LunaDress, with its ... the fashion industry. Now, the business is showing its latest ... women’s dresses. , According to the company’s CEO, all the ... now offered with big discounts, up to 80% off. All ...
(Date:1/22/2015)... TN (PRWEB) January 22, 2015 Gabe’s Chemo Duck ... Duck App, the first app ever created for kids with cancer. ... Apple phones and devices, is filled with enjoyable games to help ... and treatments. The free app helps to keep kids entertained, educated ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... diseases, including Age-Related Macular Degeneration and Diabetic ... ... Charlesson, LLC ("Charlesson"),today announced that it is the recipient of several ... and an award from the Oklahoma Center for the Advancement of ...
... -- In the 25 years since establishing the Dyslexia ... Albert Galaburda, MD, has witnessed a dramatic transformation in ... Over the years, there have been a host of ... the Division of Behavioral Neurology at BIDMC whose work ...
... - Solaris Platform is Now Supported to Help ... Supporting growing,demand within the biomedical market for ... the availability of Release 1.3,of SLIM Search. The ... and sensitivity for biomedical research and development.,Version 1.3 ...
... Food for Kids with Diabetes" by Robyn Webb, ... a child with diabetes,doesn,t have to mean making ... http://www.clevelandclinicpress.org/ ), publishing arm of Cleveland,Clinic ( http://www.clevelandclinic.org/ ... for Kids with Diabetes" by award-winning nutritionist and,columnist ...
... (Nasdaq: IMCL ) and Bristol-Myers Squibb Company ... established an agreement with Merck KGaA for,the co-development ... terms of the agreement, ImClone Systems, Bristol-Myers,Squibb and ... to develop and,following regulatory approval, market ERBITUX in ...
... aureus Infections in the, United States, shows that hospital-caused MRSA infections are ... have,consistently understated the size of the problem and have failed to call ... from these ... infections., NEW YORK, Oct. ...
Cached Medicine News:Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 2Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 3Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 4Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 5Health News:BIDMC Dyslexia Research Lab celebrates 25th anniversary 2Health News:Release 1.3 of SLIM Search Now Available 2Health News:New Cleveland Clinic Press Healthy Cookbook Helps Diabetic Kids 2Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 2Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 3Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 4Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 5Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 6Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 7Health News:The Journal of the American Medical Association (JAMA) Article Reveals Scope of MRSA Infections 2
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of Centers ... 2015 enrollment data shows that 81 percent of seniors ... and extra discounts at certain pharmacies. The findings were ... pharmacy plans are now the foundation of Medicare Part ...
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... 14, 2011 Regulus Therapeutics Inc ., a ... medicines targeting microRNAs, today announced that it has added ... The addition of Dr. Hannon, a researcher whose work ... microRNA pathway, increases SAB membership to six pioneers in ...
... Renal Therapies Division of B. Braun Medical ... Plasmat™ Futura System for H.E.L.P. ®   LDL Apheresis ... therapy provides a more easy-to-use system for clinicians ... severe hypercholesterolemia. (Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO) ...
Cached Medicine Technology:Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 2Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 3Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 4Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 5B. Braun Renal Therapies Division Announces Availability of Advanced Apheresis Therapy System 2
Bruns bone curette, 9, oval, solid actagonal handle....
MRI curette, 8.5" overall length....
15" overall length, 5" handle....
9.5" overall length, 4.5" handle....
Medicine Products: